Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism and Excretion of [14C]MK-8189 in Healthy Adults
NCT06626464Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2022
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elpipodect in schizophrenia, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from 0 to 24 hours, Area Under the Concentration-Time Curve from Time 0 to Last and 11 more. Started May 2022; status: completed.
02
Drugs
elpipodect
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06626464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626464.